Franklin Resources
CLDX icon

Franklin Resources’s Celldex Therapeutics CLDX Stock Holding History

Franklin Resources’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,003
Closed -$780K – 2686
2023
Q2 		$780K Buy
+23,003
New +$775K ﹤0.01% 1744
2022
Q1 		– Sell
-5,301
Closed -$205K – 2452
2021
Q4 		$205K Buy
5,301
+129
+2% +$5.62K ﹤0.01% 2233
2021
Q3 		$279K Buy
+5,172
New +$243K ﹤0.01% 2108
2017
Q3 		– Sell
-829
Closed -$31K – 1484
2017
Q2 		$31K Sell
829
-350,407
-100% -$15.5M ﹤0.01% 1494
2017
Q1 		$19M Sell
351,236
-64,315
-15% -$3.35M 0.01% 799
2016
Q4 		$22.1M Sell
415,551
-4,662
-1% -$265K 0.01% 769
2016
Q3 		$25.5M Sell
420,213
-320
-0.1% -$19.9K 0.01% 737
2016
Q2 		$27.7M Sell
420,533
-183,893
-30% -$11.7M 0.01% 705
2016
Q1 		$34.3M Sell
604,426
-49,233
-8% -$5.54M 0.02% 644
2015
Q4 		$154M Buy
653,659
+48,429
+8% +$10.6M 0.08% 261
2015
Q3 		$95.7M Buy
605,230
+29,291
+5% +$8.29M 0.05% 360
2015
Q2 		$218M Sell
575,939
-2,271
-0.4% -$902K 0.1% 228
2015
Q1 		$242M Sell
578,210
-59,795
-9% -$21.4M 0.11% 208
2014
Q4 		$175M Sell
638,005
-43,825
-6% -$10.9M 0.08% 251
2014
Q3 		$133M Sell
681,830
-24,950
-4% -$5.44M 0.06% 302
2014
Q2 		$173M Buy
706,780
+47,896
+7% +$10.8M 0.08% 267
2014
Q1 		$175M Buy
658,884
+130,216
+25% +$49.9M 0.08% 255
2013
Q4 		$192M Sell
528,668
-4,374
-0.8% -$1.69M 0.09% 232
2013
Q3 		$283M Sell
533,042
-36,894
-6% -$12.7M 0.15% 166
2013
Q2 		$133M Buy
+569,936
New +$112M 0.08% 255

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Franklin Resources's CLDX Position: Q3 2023 in Review

Franklin Resources sold out of Celldex Therapeutics (CLDX) in Q3 2023, closing a stake of 23,003 shares — an estimated $780K sold.

Franklin Resources first reported a position in CLDX in Q2 2013 and held it in 20 quarters. The position peaked at $283M in Q3 2013. 144 funds tracked by Wall St. Rank hold CLDX as of Q3 2023.

  • Franklin Resources reported no remaining Celldex Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Franklin Resources sold 23,003 Celldex Therapeutics shares in Q3 2023, an estimated $780K.
  • Franklin Resources first reported a position in Celldex Therapeutics in Q2 2013 and held it in 20 quarters.
  • Franklin Resources's Celldex Therapeutics position peaked at $283M in Q3 2013.
  • 144 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2023.

Based on Franklin Resources's 13F filing for Q3 2023, filed 13 Nov 2023.